Co-occurrence of myeloid neoplasm and plasma cell neoplasm
DOI:
https://doi.org/10.4322/acr.2021.393Keywords:
Myelodysplastic Syndromes, Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma, Bone Marrow, PancytopeniaAbstract
Co-occurrence of myelodysplastic syndrome (MDS) and plasma cell neoplasm in patients with no history of chemo and/or radiotherapy is rarely reported. Herein, we report a case of a female in her seventieth decade of life who was referred to the hospital for pancytopenia. The patient was asymptomatic and was doing well overall. Serum protein electrophoresis was remarkable for a lambda-restricted monoclonal protein (IgG) estimated at 1.8g/dL. Immunoglobulin G serum level was also elevated, and serum Kappa/Lambda free light chain ratio was decreased. At that time, a bone marrow biopsy showed myelodysplastic syndrome with excess blasts-2 (MDS-EB2) and a monoclonal plasma cell proliferation. Some studies have shown that patients with plasma cell neoplasm could be associated with an increased risk of developing MDS compared to the general population. Based on reviewing the literature, to our knowledge, the pathological mechanism of the co-occurrence of both diseases is not yet clear.
Downloads
References
Giagounidis A. Myelodysplastische syndrome. Internist (Berl). 2013;54(6):699-708. http://dx.doi.org/10.1007/s00108-012-3214-3. PMID: 23657619.
Dotson JL, Lebowicz Y. Myelodysplastic syndrome. Treasure Island (FL): StatPearls Publishing; 2021. PMID: 30480932.
Hasserjian RP. Myelodysplastic syndrome updated. Pathobiology. 2019;86(1):7-13. http://dx.doi.org/10.1159/000489702. PMid:30041243.
Kennedy JA, Ebert BL. Clinical implications of genetic mutations in myelodysplastic syndrome. J Clin Oncol. 2017;35(9):968-74. http://dx.doi.org/10.1200/JCO.2016.71.0806. PMid:28297619.
Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12):e538-48. http://dx.doi.org/10.1016/S1470-2045(14)70442-5. PMid:25439696.
Michels TC, Petersen KE. Multiple Myeloma: diagnosis and treatment. Am Fam Physician. 2017;95(6):373-83. PMid:28318212.
Rajkumar SV. Evolving diagnostic criteria for multiple myeloma. Hematology (Am Soc Hematol Educ Program). 2015;2015(1):272-8. http://dx.doi.org/10.1182/asheducation-2015.1.272. PMid:26637733.
Yang J, Terebelo HR, Zonder JA. Secondary primary malignancies in multiple myeloma: an old NEMESIS revisited. Adv Hematol. 2012;2012:801495. http://dx.doi.org/10.1155/2012/801495. PMid:22851973.
Cuzick J, Erskine S, Edelman D, Galton DA. A comparison of the incidence of the myelodysplastic syndrome and acute myeloid leukaemia following melphalan and cyclophosphamide treatment for myelomatosis. Br J Cancer. 1987;55(5):523-9. http://dx.doi.org/10.1038/bjc.1987.107. PMid:3300761.
Roeker LE, Larson DR, Kyle RA, Kumar S, Dispenzieri A, Rajkumar SV. Risk of acute leukemia and myelodysplastic syndromes in patients with monoclonal gammopathy of undetermined significance (MGUS): a population-based study of 17 315 patients. Leukemia. 2013;27(6):1391-3. http://dx.doi.org/10.1038/leu.2013.34. PMid:23380709.
Yoshida Y, Oguma S, Ohno H, et al. Co-occurrence of monoclonal gammopathy and myelodysplasia: a retrospective study of fourteen cases. Int J Hematol. 2014;99(6):721-5. http://dx.doi.org/10.1007/s12185-014-1570-6. PMid:24687918.
Klimkowska M, Nannya Y, Gran C, et al. Absence of a common founder mutation in patients with cooccurring myelodysplastic syndrome and plasma cell disorder. Blood. 2021;137(9):1260-3. http://dx.doi.org/10.1182/blood.2020007555. PMid:33120432.
Mailankody S, Pfeiffer RM, Kristinsson SY, et al. Risk of acute myeloid leukemia and myelodysplastic syndromes after multiple myeloma and its precursor disease (MGUS). Blood. 2011;118(15):4086-92. http://dx.doi.org/10.1182/blood-2011-05-355743. PMid:21795746.
Downloads
Published
Issue
Section
License
Copyright (c) 2022 Autopsy and Case Reports

This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright
Authors of articles published by Autopsy and Case Report retain the copyright of their work without restrictions, licensing it under the Creative Commons Attribution License - CC-BY, which allows articles to be re-used and re-distributed without restriction, as long as the original work is correctly cited.